Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of abemaciclib (LY2835219) in participants with stage IV squamous non-small cell lung cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer Stage IV | Phase 2 | Status: COMPLETED | Results posted: 2018-06-26